NCT00654485View on ClinicalTrials.gov

COMETS - Compare the Efficacy of Rosuvastatin With Atorvastatin and Placebo in the Treatment of Non-Diabetic, Non-Atheroscleric, Metabolic Syndrome Subjects

PHASE3CompletedINTERVENTIONAL
Enrollment

940

Participants

Timeline

Start Date

May 31, 2002

Study Completion Date

February 28, 2005

Conditions
Metabolic Syndrome
Interventions
DRUG

Rosuvastatin

DRUG

Atorvastatin

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY